Transgene unveils myvac (TM), an individualized immunotherapy against solid tumors
•myvac (TM) is a viral vector-based, individualized immunotherapy that has been developed to target solid tumors
•myvac (TM) stimulates the patient’s immune system to recognize and destroy tumors using their own cancer specific genetic mutations
•myvac (TM) is a highly innovative approach that combines the use of the tumor’s neoantigens with the Transgene’s viral vector expertise
•First patient to be treated in 2019
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer